Trial Profile
A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Hydroxychloroquine (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2018 Status changed from recruiting to completed, according to the results presented at the 19th World Conference on Lung Cancer.
- 26 Sep 2018 Results (n=75) presented at the 19th World Conference on Lung Cancer.
- 09 Dec 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.